entertainment -WSS

entertainment

author：leisure time 2025-10-01 23:31:28 - browse：3

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Study: Why relieving medical debt did not improve financial outcomes

Wikipedia

WSS

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Physicians and social media: If you see something, say something?

My daughter's legacy lives on through her writing, phage therapy

UnitedHealth increases loan offers after Change Healthcare outage

Neuroscience’s long legacy of racism

Colonoscopy prep: Liquid

hotspot

entertainment

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

Stop the failed accountable care organization experiment

Dobbs anniversary: the lost opportunity of abortion as health care

U.K. researchers warn about biases in medical devices, algorithms

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Orchard's therapy for neuron disease in children wins FDA approval

State Dept. review finds Biden bears some blame for Afghanistan failures

SCOTUS questions limit to govt efforts to fight misinformation

State Dept. review finds Biden bears some blame for Afghanistan failures

Health care court cases: Humana, Sutter, Novant

focus

Orchard's therapy for neuron disease in children wins FDA approval

Stop the failed accountable care organization experiment

New report analyzes digital physical therapy solutions' effectiveness

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Gene editing the human germline: What are the risks?

Readers discuss the intersection of pregnancy and addiction

focus

Wikipedia

Wikipedia

hotspot